Psychiatry Research
Volume 176, Issue 1 , Pages 1-7 , 30 March 2010

Tyrosine hydroxylase, interleukin-1β and tumor necrosis factor-α are overexpressed in peripheral blood mononuclear cells from schizophrenia patients as determined by semi-quantitative analysis

  • Liang Liu

      Affiliations

    • Wuxi Mental Health Center, Nanjing Medical University, Wuxi, China
    • ,
  • Fujun Jia

      Affiliations

    • The Guangdong Provincial Institute of Mental Health, 123, Huifuxi Road, Guangzhou, 510080, China
    • Corresponding Author InformationCorresponding author. Tel./fax: +86 20 81888553.
    • ,
  • Guozhen Yuan

      Affiliations

    • Wuxi Mental Health Center, Nanjing Medical University, Wuxi, China
    • ,
  • Zaohuo Chen

      Affiliations

    • Wuxi Mental Health Center, Nanjing Medical University, Wuxi, China
    • ,
  • Jianjun Yao

      Affiliations

    • Wuxi Mental Health Center, Nanjing Medical University, Wuxi, China
    • ,
  • Hengfen Li

      Affiliations

    • The Second Affiliated Hospital, XinXiang Medical College, XinXiang, China
    • ,
  • Chunxia Fang

      Affiliations

    • Wuxi Mental Health Center, Nanjing Medical University, Wuxi, China

Received 3 December 2007 ,Revised 26 August 2008 ,Accepted 23 October 2008.

References 

  1. Abreu P, Llorente E, Hernandez MM, Gonzalez MC. Interleukin-1 beta stimulates tyrosine hydroxylase activity in the median eminence. Neuroreport. 1994;5:1356–1358
  2. Akil M, Edgar CL, Pierri JN, Casali S, Lewis DA. Decreased density of tyrosine hydroxylase-immunoreactive axons in the entorhinal cortex of schizophrenic subjects. Biological Psychiatry. 2000;47:361–370
  3. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer's disease. Neurobiology of Aging. 2000;21:383–421
  4. Al-Omaishi J, Bashir R, Gendelman HE. The cellular immunology of multiple sclerosis. Journal of Leukocyte Biology. 1999;65:444–452
  5. Andreasen NC, Endicott J, Spitizer RL, Winokur G. The family history method using diagnostic criteria: reliability and validity. Archives of General Psychiatry. 1977;34:1229–1235
  6. Andreasen NC, Flaum M, Arndt S. The Comprehensive Assessment of Symtoms and History (CASH). An instrument for assessing diagnosis and paychopathology. Archives of General Psychiatry. 1992;49:615–623
  7. Angrist B, Gershon S. Clinical response to several dopamine agonists in schizophrenic and nonschizophrenic subjects. Advances in Biochemical Psychopharmacology. 1977;16:677–680
  8. Anisman H, Merali Z, Poulter MO, Hayley S. Cytokines as a precipitant of depressive illness: animal and human studies. Current Pharmaceutical Design. 2005;11:963–972
  9. Arai H, Furuya T, Yasuda T, Miura M, Mizuno Y, Mochizuki H. Neurotoxic effects of lipopolysaccharide on nigral dopaminergic neurons are mediated by microglial activation, interleukin-1beta, and expression of caspase-11 in mice. The Journal of Biological Chemistry. 2004;279:51647–51653
  10. Arolt V, Rothermundt M, Wandinger KP, Kirchner H. Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment. Molecular Psychiatry. 2000;5:150–158
  11. Baker I, Masserano J, Wyatt RJ. Serum cytokine concentrations in patients with schizophrenia. Schizophrenia Research. 1996;20:199–203
  12. Barak V, Barak Y, Levine J, Nisman B, Roisman I. Changes in interleukin-1 beta and soluble interleukin-2 receptor levels in CSF and serum of schizophrenic patients. Journal of Basic and Clinical Physiology and Pharmacology. 1995;6:61–69
  13. Bhatt S, Siegel A. Potentiating role of interleukin 2 (IL-2) receptors in the midbrain periaqueductal gray (PAG) upon defensive rage behavior in the cat: role of neurokinin NK(1) receptors. Behavioural Brain Research. 2006;167:251–260
  14. Buka SL, Tsuang MT, Torrey EF, Klebanoff MA, Wagner RL, Yolken RH. Maternal cytokine levels during pregnancy and adult psychosis. Brain, Behavior, and Immunity. 2001;15:411–420
  15. Carlsson A, Carlsson ML. A dopaminergic deficit hypothesis of schizophrenia: the path to discovery. Dialogues in Clinical Neuroscience. 2006;8:137–142
  16. Carvey PM, Chen EY, Lipton JW, Tong CW, Chang QA, Ling ZD. Intra-parenchymal injection of tumor necrosis factor-alpha and interleukin 1-beta produces dopamine neuron loss in the rat. Journal of Neural Transmission. 2005;112:601–612
  17. Cosentino M, Fietta AM, Ferrari M, Rasini E, Bombelli R, Carcano E, et al. Human CD4+CD25+ regulatory T cells selectively express tyrosine hydroxylase and contain endogenous catecholamines subserving an autocrine/paracrine inhibitory functional loop. Blood. 2007;109:632–642
  18. Crespo-Facorro B, Carrasco-Marin E, Perez-Iglesias R, Pelayo-Teran JM, Fernandez-Prieto L, Leyva-Cobian F, et al. Interleukin-12 plasma levels in drug-naive patients with a first episode of psychosis: effects of antipsychotic drugs. Psychiatry Research. 2008;158:206–216
  19. Danis VA, Millington M, Hyland VJ, Grennan D. Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clinical and Experimental Immunology. 1995;99:303–310
  20. Djoba Siawaya JF, Roberts T, Babb C, Black G, Golakai HJ, Stanley K, et al. An evaluation of commercial fluorescent bead-based luminex cytokine assays. PLoS ONE. 2008;3:e2535
  21. Ebrinc S, Top C, Oncul O, Basoglu C, Cavuslu S, Cetin M. Serum interleukin 1 alpha and interleukin 2 levels in patients with schizophrenia. The Journal of International Medical Research. 2002;30:314–317
  22. Erbagci AB, Herken H, Koyluoglu O, Yilmaz N, Tarakcioglu M. Serum IL-1beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment. Mediators of Inflammation. 2001;10:109–115
  23. Ferrari CC, Pott Godoy MC, Tarelli R, Chertoff M, Depino AM, Pitossi FJ. Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1beta in the substantia nigra. Neurobiology of Disease. 2006;24:183–193
  24. Fertuzinhos SM, Oliveira JR, Nishimura AL, Pontual D, Carvalho DR, Sougey EB, et al. Analysis of IL-1alpha, IL-1beta, and IL-1RA [correction of IL-RA] polymorphisms in dysthymia. Journal of Molecular Neuroscience. 2004;22:251–256
  25. Franceschi C, Bonafe M, Valensin S, Olivieri F, De Luca M, Ottaviani E, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Annals of the New York Academy of Sciences. 2000;908:244–254
  26. Halford WP. The essential prerequisites for quantitative RT-PCR. Nature Biotechnology. 1999;17:835
  27. Hanninen K, Katila H, Rontu R, Mattila KM, Hurme M, Lehtimaki T. Tumor necrosis factor-alpha –G308A polymorphism in schizophrenia in a Finnish population. Neuroscience Letters. 2005;385:76–81
  28. Hirsch EC, Breidert T, Rousselet E, Hunot S, Hartmann A, Michel PP. The role of glial reaction and inflammation in Parkinson's disease. Annals of the New York Academy of Sciences. 2003;991:214–228
  29. Hori H, Yoshimura R, Yamada Y, Ikenouchi A, Mitoma M, Ida Y, et al. Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients. International Clinical Psychopharmacology. 2007;22:21–27
  30. Ichinose H, Ohye T, Fujita K, Pantucek F, Lange K, Riederer P, et al. Quantification of mRNA of tyrosine hydroxylase and aromatic L-amino acid decarboxylase in the substantia nigra in Parkinson's disease and schizophrenia. Journal of Neural Transmission. Parkinson's Disease and Dementia Section. 1994;8:149–158
  31. Ito R, Asami S, Kagawa S, Motohashi S, Shichino H, Chin M, et al. Usefulness of tyrosine hydroxylase mRNA for diagnosis and detection of minimal residual disease in neuroblastoma. Biological & Pharmaceutical Bulletin. 2004;27:315–318
  32. Jacewicz R, Szram S, Galecki P, Berent J. Will genetic polymorphism of tetranucleotide sequences help in the diagnostics of major psychiatric disorders?. Forensic Science International. 2006;162:24–27
  33. Jarskog LF, Xiao H, Wilkie MB, Lauder JM, Gilmore JH. Cytokine regulation of embryonic rat dopamine and serotonin neuronal survival in vitro. International Journal of Developmental Neuroscience. 1997;15:711–716
  34. Jiang JL, Qiu YH, Peng YP, Wang JJ. Immunoregulatory role of endogenous catecholamines synthesized by immune cells. Sheng Li Xue Bao. 2006;58:309–317
  35. Jin G, Tan X, Tian M, Qin J, Zhu H, Huang Z, et al. The controlled differentiation of human neural stem cells into TH-immunoreactive (ir) neurons in vitro. Neuroscience Letters. 2005;386:105–110
  36. Johnson JD, Campisi J, Sharkey CM, Kennedy SL, Nickerson M, Greenwood BN, et al. Catecholamines mediate stress-induced increases in peripheral and central inflammatory cytokines. Neuroscience. 2005;135:1295–1307
  37. Kapsimalis F, Richardson G, Opp MR, Kryger M. Cytokines and normal sleep. Current Opinion in Pulmonary Medicine. 2005;11:481–484
  38. Katila H, Appelberg B, Hurme M, Rimon R. Plasma levels of interleukin-1 beta and interleukin-6 in schizophrenia, other psychoses, and affective disorders. Schizophrenia Research. 1994;12:a29–34
  39. Katila H, Hanninen K, Hurme M. Polymorphisms of the interleukin-1 gene complex in schizophrenia. Molecular Psychiatry. 1999;4:179–181
  40. Kavelaars A, van Der Voort CR, Heijnen CJ. Adrenergic receptor subtypes in human peripheral blood lymphocytes. Hypertension. 1999;34:e5
  41. Khan MM, Sansoni P, Silverman ED, Engleman EG, Melmon KL. Beta-adrenergic receptors on human suppressor, helper, and cytolytic lymphocytes. Biochemical Pharmacology. 1986;35:1137–1142
  42. Kiecolt-Glaser JK, Glaser R. Depression and immune function: central pathways to morbidity and mortality. Journal of Psychosomatic Research. 2002;53:873–876
  43. Kim HY, Rikihisa Y. Expression of interleukin-1beta, tumor necrosis factor alpha, and interleukin-6 in human peripheral blood leukocytes exposed to human granulocytic ehrlichiosis agent or recombinant major surface protein P44. Infection and Immunity. 2000;68:3394–3402
  44. Kim YK, Myint AM, Lee BH, Han CS, Lee HJ, Kim DJ, et al. Th1, Th2 and Th3 cytokine alteration in schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2004;28:1129–1134
  45. Kurumaji A, Kuroda T, Yamada K, Yoshikawa T, Toru M. An association of the polymorphic repeat of tetranucleotide (TCAT) in the first intron of the human tyrosine hydroxylase gene with schizophrenia in a Japanese sample. Journal of Neural Transmission. 2001;108:489–495
  46. Larson SJ. Behavioral and motivational effects of immune-system activation. The Journal of General Psychology. 2002;129:401–414
  47. Levine SZ, Rabinowitz J. Revisiting the 5 dimensions of the Positive and Negative Syndrome Scale. Journal of Clinical Psychopharmacology. 2007;27:431–436
  48. Lindenmayer JP, Bernstein-Hyman R, Grochowski S. A new five factor model of schizophrenia. The Psychiatric Quarterly. 1994;65:299–322
  49. Lipska BK, Lerman DN, Khaing ZZ, Weinberger DR. The neonatal ventral hippocampal lesion model of schizophrenia: effects on dopamine and GABA mRNA markers in the rat midbrain. The European Journal of Neuroscience. 2003;18:3097–3104
  50. Mallet J. The TiPS/TINS lecture. Catecholamines: from gene regulation to neuropsychiatric disorders. Trends in Neurosciences. 1996;19:191–196
  51. Matthysse S. Antipsychotic drug actions: a clue to the neuropathology of schizophrenia?. Federation Proceedings. 1973;32:200–205
  52. Melchitzky DS, Lewis DA. Tyrosine hydroxylase- and dopamine transporter-immunoreactive axons in the primate cerebellum. Evidence for a lobular- and laminar-specific dopamine innervation. Neuropsychopharmacology. 2000;22:466–472
  53. MohanKumar SM, MohanKumar PS. Systemic Interleukin-1beta stimulates the simultaneous release of norepinephrine in the paraventricular nucleus and the median eminence. Brain Research Bulletin. 2005;65:451–456
  54. Monteleone P, Fabrazzo M, Tortorella A, Maj M. Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment. Psychiatry Research. 1997;71:11–17
  55. Morar B, Schwab SG, Albus M, Maier W, Lerer B, Wildenauer DB. Evaluation of association of SNPs in the TNF alpha gene region with schizophrenia. American journal of medical genetics. Part B, Neuropsychiatric genetics. 2006;144B:318–324
  56. Müller N, Ackenheil M. Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 1998;22:1–33
  57. Muller N, Riedel M, Gruber R, Ackenheil M, Schwarz MJ. The immune system and schizophrenia. An integrative view. Annals of the New York Academy of Sciences. 2000;917:456–467
  58. Mullington JM, Hinze-Selch D, Pollmacher T. Mediators of inflammation and their interaction with sleep: relevance for chronic fatigue syndrome and related conditions. Annals of the New York Academy of Sciences. 2001;933:201–210
  59. Musso NR, Brenci S, Setti M, Indiveri F, Lotti G. Catecholamine content and in vitro catecholamine synthesis in peripheral human lymphocytes. The Journal of clinical Endocrinology and Metabolism. 1996;81:3553–3557
  60. Naudin J, Capo C, Giusano B, Mege JL, Azorin JM. A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia?. Schizophrenia Research. 1997;26:227–233
  61. Pae CU, Kim JJ, Serretti A, Lee CU, Lee SJ, Lee C, et al. VNTR polymorphism of tyrosine hydroxylase gene and schizophrenia in the Korean population. Neuropsychobiology. 2003;47:131–136
  62. Papiol S, Rosa A, Gutierrez B, Martin B, Salgado P, Catalan R, et al. Interleukin-1 cluster is associated with genetic risk for schizophrenia and bipolar disorder. Journal of Medical Genetics. 2004;41:219–223
  63. Pochet R, Delespesse G, Gausset PW, Collet H. Distribution of beta-adrenergic receptors on human lymphocyte subpopulations. Clinical and Experimental Immunology. 1979;38:578–584
  64. Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biological Psychiatry. 2008;63:801–808
  65. Qiu YH, Peng YP, Jiang JM, Wang JJ. Expression of tyrosine hydroxylase in lymphocytes and effect of endogenous catecholamines on lymphocyte function. Neuroimmunomodulation. 2004;11:75–83
  66. Qiu YH, Cheng C, Dai L, Peng YP. Effect of endogenous catecholamines in lymphocytes on lymphocyte function. Journal of Neuroimmunology. 2005;167:45–52
  67. Rodriguez-Pallares J, Guerra MJ, Labandeira-Garcia JL. Angiotensin II and interleukin-1 interact to increase generation of dopaminergic neurons from neurospheres of mesencephalic precursors. Brain research. Developmental Brain Research. 2005;158:120–122
  68. Roiz-Santianez R, Crespo-Facorro B, Perez-Iglesias R, Pelayo-Teran JM, Carrasco-Marin E, Mata I, et al. Interleukin-1 receptor antagonist genotype and brain morphometry in first-episode non-affective psychosis. Psychiatry Research. 2008;162:167–171
  69. Sanders VM, Baker RA, Ramer-Quinn DS, Kasprowicz DJ, Fuchs BA, Street NE. Differential expression of the beta2-adrenergic receptor by Th1 and Th2 clones: implications for cytokine production and B cell help. Journal of Immunology. 1997;158:4200–4210
  70. Seeman P, Schwarz J, Chen JF, Szechtman H, Perreault M, McKnight GS, et al. Psychosis pathways converge via D2high dopamine receptors. Synapse. 2006;60:319–346
  71. Solfrizzi V, D'Introno A, Colacicco AM, Capurso C, Todarello O, Pellicani V, et al. Circulating biomarkers of cognitive decline and dementia. Clinica Chimica Acta; International Journal of Clinical Chemistry. 2006;364:91–112
  72. Sriram K, Miller DB, O'Callaghan JP. Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha. Journal of Neurochemistry. 2006;96:706–718
  73. Steiner AA, Chakravarty S, Robbins JR, Dragic AS, Pan J, Herkenham M, et al. Thermoregulatory responses of rats to conventional preparations of lipopolysaccharide are caused by lipopolysaccharide per se — not by lipoprotein contaminants. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 2005;289:R348–R352
  74. Stone JM, Morrison P, Pilowsky LS. Glutamate and dopamine dysregulation in schizophrenia — a synthesis and selective review. Journal of Psychopharmacology. 2007;21:440–452
  75. Watkins LR, Milligan ED, Maier SF. Glial proinflammatory cytokines mediate exaggerated pain states: implications for clinical pain. Advances in Experimental Medicine and Biology. 2003;521:1–21
  76. Weickert CS, Webster MJ, Gondipalli P, Rothmond D, Fatula RJ, Herman MM, et al. Postnatal alterations in dopaminergic markers in the human prefrontal cortex. Neuroscience. 2007;144:1109–1119
  77. Wei J, Ramchand CN, Hemmings GP. Association of polymorphic VNTR region in the first intron of the human TH gene with disturbances of the catecholamine pathway in schizophrenia. Psychiatric Genetics. 1995;5:83–88
  78. Wei J, Ramchand CN, Clark AE, Hemmings GP. A study of enzymes involved in catecholamine metabolism in parents of patients with schizophrenia. Schizophrenia Research. 1996;19:27–32
  79. Wieseler-Frank J, Maier SF, Watkins LR. Central proinflammatory cytokines and pain enhancement. Neurosignals. 2005;14:166–174
  80. Xu HM, Wei J, Hemmings GP. Changes of plasma concentrations of interleukin-1 alpha and interleukin-6 with neuroleptic treatment for schizophrenia. The British Journal of Psychiatry: The Journal of Mental Science. 1994;164:251–253
  81. Zai G, Muller DJ, Volavka J, Czobor P, Lieberman JA, Meltzer HY, et al. Family and case-control association study of the tumor necrosis factor-alpha (TNF-alpha) gene with schizophrenia and response to antipsychotic medication. Psychopharmacology. 2006;188:171–182

PII: S0165-1781(08)00392-2

doi: 10.1016/j.psychres.2008.10.024

Psychiatry Research
Volume 176, Issue 1 , Pages 1-7 , 30 March 2010

Article Tools

* Image Usage & Resolution